In addition, when considering inhibitors of CAIX, LOX, or CXCR4, selection of patients should be based on examination of expression levels of these target genes in tumor biopsies or by PET imaging based on tumour retention of radiolabeled antibodies (for example, against CAIX). The gene discussed is LOX; the disease is neoplasm.